9 Darly Bursch and co-workers (Karn, J., Busch, D., Nature 1966, 211, 160) synthesized a Ni(II)-aminopyridine complex using a metal-templatecondensation reaction shown below. While compound C is the target compound, other Ni complexes can be produced as intermediates of thereaction.Hн онHH2NH2N-Ni(CIO4)2+HN'N Ni²* HN´ 2 CIO4'N Ni2* HN2 CIO,`N Ni2* HN2 CIO4H2O-ELOHrefluxH2N.N.N.HHABWhat SPECIFIC spectral features in IR and MS do you expect to see in order to determine if the reaction is COMPLETE?SAMPLE ANSWER:-1cmIn IR: (1) Presence of OH stretch at(2) Absence of C=C band atcm 1In MS: m/z = 250 and 157

The solution of the question is given below:

Darly Bursch and co-workers (Karn, J., Busch, D., Nature 1966, 211, 160) synthesized a Ni(lI)-aminopyridine complex using a metal-template condensation reaction shown below. While compound C is the target compound, other Ni complexes can be produced as intermediates of the reaction. н он H2N H2N- Ni(CIO4)2 'N Ni2* HN 2 CIO4 `N Ni²* HN 2 CIO, `N Ni2* HN 2 CIO, N + HN H2O-ELOH reflux H2N. N. H H A B What SPECIFIC spectral features in IR and MS do you expect to see in order to determine if the reaction is COMPLETE?

Darly Bursch and co-workers (Karn, J., Busch, D., Nature 1966, 211, 160) synthesized a Ni(lI)-aminopyridine complex using a metal-template condensation reaction shown below. While compound C is the target compound, other Ni complexes can be produced as intermediates of the reaction. н он H2N H2N- Ni(CIO4)2 'N Ni2* HN 2 CIO4 `N Ni²* HN 2 CIO, `N Ni2* HN 2 CIO, N + HN H2O-ELOH reflux H2N. N. H H A B What SPECIFIC spectral features in IR and MS do you expect to see in order to determine if the reaction is COMPLETE?

Appl Of Ms Excel In Analytical Chemistry

2nd Edition

ISBN:9781285686691

Author:Crouch

Publisher:Crouch

Chapter12: Spectrochemical Methods

Section: Chapter Questions

Problem 13P

See similar textbooks

Similar questions

Give the synthesis pathway to synthesize the complex of trans-[PtCl2(en)(tu)] (structure below) by given the trans effect order is tu > Cl > en.
draw the electronic configuration of platinium IIII in ormaplatine (complex and expect the followings: a. the charge of this drug b. the shape of its complex. c. the expected type of hybridization d. the number of coordination covalent bonds in this drug e. what is the pharmacological use of ormaplatinePlease explain the point (d) and how I can calculate it
Which do you expect to have a greater binding constant (equilibrium constant for binding to the metal), ethylenediamine (en) or tris(2-aminoethyl)amine (tren)?
what is the Ligand receptor interaction prediction of the structure in the picture that i attached thank you
calculat dlta E for each complex Trans complex : G= 355 microsiemens λ= 450 nm Cis complex : G=250 microsiemens λ=500 nm.
) Describe the substitution process for the reaction of Cisplatin and the guanine nucleobase with a focus on what is happening at the metal center and demonstrate your understanding of the kinetic factors involved. b) What advantages or disadvantages for the anticancer drug properties would result from using a Cisplatin-analog that has a faster rate of ligand substitution?
1) calculate the values of the rate constant k-1, and the value of the dissociation constant of the ES-Complex, Ks with appropriate units 2) calculate the total amount of enzyme used in the experiment and the catalytic efficiency ratio
show the reaction mechanism formation of Co(III) acetylacetonate from CoCO3 dissolved in acetylacetone, ammonia and 2ml of acetylacetonate with 10% aqueous hydrogen peroxide. show the arrangement of the ligand around the complex
Assign the following as Ror S.
19. The association constant of protein X for ligand Y is: 100 micromolar. At what concentration of ligand is half fo the protein bound?
cystine is made up of two cysteine residues joined by a disulfide bond. explain why the two carboxylgroups have different pka values, even though they both have the same ligands. along the same linesexplain why the pka values of the two amino groups differ even more.
What is the correct nomenclature for the complex ion given below? A. di-µ-amido-hydroxobis (diamethylenediamnincbalt (III)) ion B. µ-imido-µ-hydroxobis (diaminbisethylenediaminkobalt (II)) ion C. µ-amido-µ-hydroxobis (amethyleneaminkbalt (III)) ion D. di-µ-amido-µ-hydroxobis (amethyleneaminkbalt (II)) ion E. µ-amido-µ-hydroxobis (diamethylenediaminkobalt (III)) ion